ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0558

Molecular Interplay Between Mammalian Target of Rapamycin (mTOR) and the YAP Pathway Mediates Rheumatoid Arthritis Synovial Fibroblast Activation

Brianne Barker1, Megan Hanlon2, Siobhan Wade1, Douglas Veale3, Ursula Fearon1 and Mary Canavan4, 1Trinity College Dublin, Dublin, Ireland, 2Molecular Rheumatology, Dublin, Ireland, 3St. Vincent's University Hospital, Blackrock, Dublin, Ireland, 4Trinity College, Dublin, Ireland

Meeting: ACR Convergence 2022

Keywords: Fibroblasts, Synovial, immunology, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Abstracts: Cytokines and Cell Trafficking

Session Type: Abstract Session

Session Time: 8:00AM-9:00AM

Background/Purpose: mTOR is a metabolic master regulator of both innate and adaptive immunity, however its exact role in synovial fibroblasts is unknown. RA synovial fibroblasts (RASFC) are known to mediate cartilage destruction and bone degradation. We therefore aimed to explore the molecular role of mTOR in RASFC activation, metabolism and invasion. Furthermore, we also aimed to explore the role of the Hippo-YAP pathway in RASFC and determine if molecular crosstalk between the pathways meditates RASFC activation.

Methods: Healthy control (HC) and RA synovial fibroblasts were stained for mTOR and analysed by Flow Cytometry. RNA-Seq analysis was performed on HC, Individuals At Risk (IAR) and RA synovial tissue biopsies. Data was analysed to detect differential gene and pathway expression and was deposited in GEO database (GSE89408). RASFC were cultured in the presence of TNFα (1ng/ml) alone or in combination with the mTOR inhibitor Rapamycin (100nM) or YAP inhibitor Verteporfin (50nM). ELISA, RT-PCR and Flow Cytometry were used to measure cytokine/chemokine production and expression of adhesion markers. Cellular invasion was assessed using Matrigel invasion assays while cellular bioenergetics was assessed using Seahorse XFe-Technology.

Results: RNASeq analysis demonstrated differential expression of genes related to the mTOR pathway in HC v RA synovial biopsies. Specifically mTOR was significantly increased in RA fibroblasts compared to HC (p< 0.05). Rapamycin inhibits TNFα mediated mTOR activatiotn (pS6 induction (p< 0.05) while also inhibiting TNFα induced ECAR (measure of glycolysis), OCR (measure of OXPHOS) and ATP synthesis in addition to several glycolytic genes (HK2, G6PD, p< 0.05). Rapamycin significantly decreases cytokines/chemokines IL-6, MCP-1, RANTES, adhesion molecules ICAM-1 and MMPs (MMP-1; all p< 0.05) while also inhibiting TNFα induced migration and invasion (both p< 0.05). Mechanistically, TNFα induces YAP expression which is abrogated in the presence of Rapamycin. TNFα induced MMP-1/MMP-3 expression and RASFC invasion is abrogated in the presence of YAP inhibition. Finally, RNASeq analysis revealed increased expression of mTOR pathway signature in IAR suggesting its potential role in early disease initiation.

Conclusion: Molecular crosstalk via the mTOR and YAP pathways mediate RASFC proinflammatory mechanisms.

Supporting image 1

mTOR pathway drives metabolic reprogramming in RASFC


Disclosures: B. Barker, None; M. Hanlon, None; S. Wade, None; D. Veale, AbbVie/Abbott, Pfizer, Eli Lilly, Novartis, Gilead; U. Fearon, AbbVie/Abbott, Pfizer, Janssen, Eli Lilly, GlaxoSmithKlein(GSK); M. Canavan, None.

To cite this abstract in AMA style:

Barker B, Hanlon M, Wade S, Veale D, Fearon U, Canavan M. Molecular Interplay Between Mammalian Target of Rapamycin (mTOR) and the YAP Pathway Mediates Rheumatoid Arthritis Synovial Fibroblast Activation [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/molecular-interplay-between-mammalian-target-of-rapamycin-mtor-and-the-yap-pathway-mediates-rheumatoid-arthritis-synovial-fibroblast-activation/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/molecular-interplay-between-mammalian-target-of-rapamycin-mtor-and-the-yap-pathway-mediates-rheumatoid-arthritis-synovial-fibroblast-activation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology